These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1617895)

  • 1. Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.
    Uddhammar A; Rantapåå-Dahlqvist S; Nilsson TK
    Clin Rheumatol; 1992 Jun; 11(2):211-5. PubMed ID: 1617895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines and adhesion molecules in patients with polymyalgia rheumatica.
    Uddhammar A; Sundqvist KG; Ellis B; Rantapää-Dahlqvist S
    Br J Rheumatol; 1998 Jul; 37(7):766-9. PubMed ID: 9714354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII-von Willebrand factor in giant cell arteritis and polymyalgia rheumatica.
    Persellin ST; Daniels TM; Rings LJ; Kazmier FJ; Bowie EJ; Hunder GG
    Mayo Clin Proc; 1985 Jul; 60(7):457-62. PubMed ID: 3925247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow up of von Willebrand factor and plasminogen activator inhibitor-1 in patients with polymyalgia rheumatica.
    Uddhammar A; Rantapää-Dahlqvist S; Nilsson TK
    Ann Rheum Dis; 1997 Nov; 56(11):698-9. PubMed ID: 9462179
    [No Abstract]   [Full Text] [Related]  

  • 5. Elevation of von Willebrand factor is independent of erythrocyte sedimentation rate and persists after glucocorticoid treatment in giant cell arteritis.
    Federici AB; Fox RI; Espinoza LR; Zimmerman TS
    Arthritis Rheum; 1984 Sep; 27(9):1046-9. PubMed ID: 6332630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease.
    Ozoran K; Dügün N; Gürler A; Tutkak H; Tokgöz G
    Scand J Rheumatol; 1995; 24(6):376-82. PubMed ID: 8610223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative study of von Willebrand factor in patients with temporal arteritis].
    González-Gay MA; Alvarez MD; Machín AJ; Alonso MD; García González J; Cereijo MJ; Bal M
    An Med Interna; 1992 Oct; 9(10):483-6. PubMed ID: 1420759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Von Willebrand factor in the outcome of temporal arteritis.
    Cid MC; Monteagudo J; Oristrell J; Vilaseca J; Pallarés L; Cervera R; Font C; Font J; Ingelmo M; Urbano-Márquez A
    Ann Rheum Dis; 1996 Dec; 55(12):927-30. PubMed ID: 9014589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica.
    Schreiber S; Buyse M
    Clin Rheumatol; 1995 May; 14(3):315-8. PubMed ID: 7641508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis.
    Nordborg E; Andersson R; Tengborn L; Edén S; Bengtsson BA
    Ann Rheum Dis; 1991 May; 50(5):316-20. PubMed ID: 2042987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Von Willebrand factor in polymyalgia rheumatica and giant cell arteritis.
    Uddhammar AC
    Clin Exp Rheumatol; 2000; 18(4 Suppl 20):S32-3. PubMed ID: 10948757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis.
    Wållberg-Jonsson S; Dahlén GH; Nilsson TK; Rånby M; Rantapää-Dahlqvist S
    Clin Rheumatol; 1993 Sep; 12(3):318-24. PubMed ID: 8258230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction.
    Andreotti F; Roncaglioni MC; Hackett DR; Khan MI; Regan T; Haider AW; Davies GJ; Kluft C; Maseri A
    J Am Coll Cardiol; 1990 Dec; 16(7):1553-60. PubMed ID: 2123906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.
    Salvarani C; Cantini F; Niccoli L; Macchioni P; Consonni D; Bajocchi G; Vinceti M; Catanoso MG; Pulsatelli L; Meliconi R; Boiardi L
    Arthritis Rheum; 2005 Feb; 53(1):33-8. PubMed ID: 15696567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica.
    Owen CE; McMaster C; Liew DFL; Leung JL; Scott AM; Buchanan RRC
    Int J Rheum Dis; 2021 Jan; 24(1):56-62. PubMed ID: 33043616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolytic and inflammatory processes in pleural effusions.
    Philip-Joët F; Alessi MC; Philip-Joët C; Aillaud M; Barriere JR; Arnaud A; Juhan-Vague I
    Eur Respir J; 1995 Aug; 8(8):1352-6. PubMed ID: 7489803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.
    Kyle V; Hazleman BL
    Ann Rheum Dis; 1989 Aug; 48(8):658-61. PubMed ID: 2782975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological and immunohistochemical determination of von Willebrand factor antigen in serum and biopsy specimens from patients with arteritis temporalis and polymyalgia rheumatica.
    Olsson A; Elling P; Elling H
    Clin Exp Rheumatol; 1990; 8(1):55-8. PubMed ID: 2189625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of measuring soluble interleukin-2 receptor in polymyalgia rheumatica.
    Gripenberg M; Franzén P; Fröseth B
    Scand J Rheumatol; 1995; 24(1):26-8. PubMed ID: 7863274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of endothelial-derived haemostatic factors in autoimmune thrombocytopenia and haemolytic anaemia.
    Nilsson TK; Sondell KM; Norberg BO; Bäck O
    J Intern Med; 1990 Sep; 228(3):249-52. PubMed ID: 2119418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.